{"chain_id": "chain_000000", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5948914", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5948914, is the following pharmacogenomic claim supported or contradicted: Genotypes GT + TT are not associated with overall survival when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is **supported**. The paper indicates that the specific genotypes (GT + TT) are not associated with overall survival when compared to the GG genotype for the SNPs studied."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2231142 and gemcitabine in Disease:Non-Small Cell Lung Carcinoma (PMCID PMC5948914), what p-value was reported for this association?", "answer": "= 0.080", "response": "The reported p-value for the association of rs2231142 (ABCG2 Q141K) with patient outcome in Non-Small Cell Lung Carcinoma treated with gemcitabine is **0.007**."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "True."}]}
{"chain_id": "chain_000001", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC11732454", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC11732454, is the following pharmacogenomic claim supported or contradicted: HLA-A *31:03 is associated with decreased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine, lamotrigine or phenytoin. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is **contradicted**. The study does not support the association of HLA-A *31:03* with a decreased likelihood of Stevens-Johnson Syndrome (SJS) when treated with carbamazepine, lamotrigine, or phenytoin."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents **clinical_association**."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of HLA-A*31:03 and carbamazepine, lamotrigine, phenytoin in Toxicity (PMCID PMC11732454), what confidence interval was reported?", "answer": "0.13\u20130.27", "response": "The study did not report a confidence interval for HLA-A*31:03 in relation to carbamazepine, lamotrigine, or phenytoin in the context of toxicity. The specific allele HLA-A*31:03 was not mentioned in the results regarding significant associations with adverse reactions."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "**False.** The confidence interval for the odds ratio (OR) associated with HLA-A*31:03 was not reported in the study, and therefore, it cannot be determined whether it excludes the null value of 1.0. Additionally, HLA-A*31:03 was not identified as significantly associated with the outcomes in the study."}]}
{"chain_id": "chain_000002", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4640545", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4640545, is the following pharmacogenomic claim supported or contradicted: Genotype CC is not associated with metabolism of carbamazepine in people with Epilepsy as compared to genotypes CT + TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2298771 and carbamazepine in Disease:Epilepsy (PMCID PMC4640545), what p-value was reported for this association?", "answer": "> 0.05", "response": "The p-value reported for the association of rs2298771 (SCN1A c.3184A>G) with carbamazepine in epilepsy was not significant, as it was stated that no impact for the SCN1A c.3184A>G SNP was observed, indicating a p-value greater than 0.05."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000003", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4177494", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4177494, is the following pharmacogenomic claim supported or contradicted: Genotypes GG + GT is associated with decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The study indicates that the presence of the rs8099917 G allele (which includes genotypes GG and GT) is associated with a lack of response to peginterferon and ribavirin therapy in HCV patients, compared to those with the TT genotype."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs8099917 and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin in Disease:Hepatitis C virus infection (PMCID PMC4177494), what OR was reported?", "answer": "7.9", "response": "The odds ratio (OR) reported for the association of the rs8099917 G allele with null-response to therapy was 7.9."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "True. The confidence interval for the OR (95% CI: 1.99-31.18) does not include the null value of 1.0."}]}
{"chain_id": "chain_000004", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC7351433", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC7351433, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1801131 and methotrexate in Other:Acute lymphoblastic leukemia (PMCID PMC7351433), what p-value was reported for this association?", "answer": "> 0.05", "response": "The p-value reported for the association of rs1801131 with decreased hepatic toxicity was P<0.05."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "True."}]}
{"chain_id": "chain_000005", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3909071", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3909071, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs13242038 and heroin in Other (PMCID PMC3909071)?", "answer": 619, "response": "The study included 619 controls."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "True"}]}
{"chain_id": "chain_000006", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5519037", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5519037, is the following pharmacogenomic claim supported or contradicted: Genotypes CT + TT are not associated with concentrations of everolimus in women with Breast Neoplasms as compared to genotype CC. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The study found that the CYP3A4 rs35599367 variant (CYP3A4*22 allele) carriers had higher everolimus blood concentration compared to wild type patients (CC genotype), indicating that the CT + TT genotypes are associated with higher concentrations of everolimus."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents a clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs776746 and everolimus in Disease:Breast Neoplasms (PMCID PMC5519037), what p-value was reported for this association?", "answer": "> 0.05", "response": "The study did not report a p-value for the association of rs776746 (CYP3A5) with everolimus concentrations in breast neoplasms, as it found no significant differences for CYP3A5*1 carriers. Therefore, no specific p-value is provided for this association in the paper."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "False."}]}
{"chain_id": "chain_000007", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5207665", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5207665, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with response to bevacizumab in women with Breast Neoplasms as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "The claim is supported. The paper indicates that specific SNPs in angiogenesis-related genes were associated with pathologic complete response (pCR) to bevacizumab, but it does not provide evidence that allele A is associated with response compared to allele G. Therefore, the claim that allele A is not associated with response is consistent with the findings."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "The annotation represents clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs17577 and bevacizumab in Disease:Breast Neoplasms (PMCID PMC5207665)?", "answer": 33, "response": "The study did not include controls specifically for rs17577 in the context of bevacizumab and breast neoplasms. The paper mentions healthy, cancer-free subjects as controls, but it does not specify the number of controls for rs17577. Therefore, the exact number of controls for that specific SNP is not provided in the study."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "False. The study does not specify the number of controls for rs17577, and it does not provide a clear count of controls that would meet the minimum of N \u2265 30."}]}
{"chain_id": "chain_000008", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC1689719", "num_turns": 4, "model": "gpt-4o-mini", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC1689719, is the following pharmacogenomic claim supported or contradicted: G6PD deficiency is not associated with Hemolysis when treated with trimethoprim. Answer one of: supported, contradicted.", "answer": "supported", "response": "Supported."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "Clinical association."}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of G6PD deficiency and trimethoprim in Toxicity (PMCID PMC1689719)?", "answer": 8, "response": "The study included 12 cases of G6PD deficiency and trimethoprim in toxicity."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": false, "response": "False."}]}
